IFNAR

Cat. No.

A24325

CAS No.

2763602-16-8

Icotrokinra (JNJ-77242113)

Synonyms: JNJ-2113; PN-235; JNJ-77242113

Icotrokinra (JNJ-77242113) is an orally available and selective antagonist of the interleukin-23 (IL-23) receptor. It potently inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC₅₀ = 5.6 pM) and suppresses IL-23-induced interferon-γ (IFN-γ) production in natural killer (NK) cells (IC₅₀ = 18.4 pM). Icotrokinra also demonstrates anti-inflammatory activity in a rat TNBS-induced colitis model. It is a promising therapeutic candidate for the study and treatment of inflammatory conditions such as psoriasis, psoriatic arthritis, and inflammatory bowel disease (IBD).

Cat. No.

A64839

CAS No.

158040-83-6

IFN-γ Antagonist 1

IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) functions as an antagonist of interferon-γ (IFN-γ). This compound effectively inhibits IFN-γ-induced HLR/DR antigen expression in cellular models. Its application is particularly relevant in the investigation of diseases characterized by dysregulation of immune responses.

Cat. No.

A64873

CAS No.

69938-75-6

CP-28888

Synonyms: CP 28888-27

CP-28888 is an interferon alpha/beta receptor (IFNAR) inducer that enhances the immune response by promoting the production of type I interferons. It exhibits greater potency in murine models, making it a valuable tool for studying immune modulation and antiviral responses in preclinical research. Despite its limited efficacy in human trials and lack of antirhinovirus activity, CP-28888 remains a relevant compound in the investigation of therapeutic approaches targeting interferon pathways.